Edition:
India

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

3.59USD
8:38pm IST
Change (% chg)

$0.07 (+1.99%)
Prev Close
$3.52
Open
$3.55
Day's High
$3.60
Day's Low
$3.48
Volume
51,600
Avg. Vol
269,998
52-wk High
$6.30
52-wk Low
$3.02

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals Posts Q4 Loss Per Share of $0.34
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS REPORTS 2018 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.34.QTRLY TOTAL REVENUE WAS $2.5 MILLION VERSUS $8.8 MILLION.  Full Article

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Thursday, 14 Feb 2019 

Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING.INOVIO PHARMACEUTICALS INC - INTENTION TO OFFER $65 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2024.INOVIO PHARMACEUTICALS -NOTES WILL BE SENIOR UNSECURED INOVIO OBLIGATIONS AND WILL ACCRUE INTEREST PAYABLE SEMIANNUALLY IN ARREARS.  Full Article

Inovio, Korean Partner Dose First Subject In Trial To Develop World's First Vaccine To Prevent Hepatitis C Infection
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO AND KOREAN PARTNER DOSE 1ST SUBJECT IN TRIAL TO DEVELOP WORLD'S FIRST VACCINE TO PREVENT HEPATITIS C INFECTION.  Full Article

Inovio Partners With Aids Malignancy Consortium To Advance Inovio’S HPV Therapy
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PARTNERS WITH AIDS MALIGNANCY CONSORTIUM TO ADVANCE INOVIO’S HPV THERAPY FOR HIGH-GRADE ANAL DYSPLASIA IN HIV-POSITIVE PATIENTS.INOVIO PHARMACEUTICALS INC - FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED.INOVIO PHARMACEUTICALS - AMC WILL FUND PHASE 2 CLINICAL TRIAL TO EVALUATE EFFICACY OF VGX-3100 IN ADULT MEN AND WOMEN WITH HUMAN PAPILLOMAVIRUS (HPV)-RELATED HIGH-GRADE ANAL DYSPLASIA OR SQUAMOUS INTRAEPITHELIAL LESIONS (ASIL) AND HIV.  Full Article

Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​
Thursday, 15 Mar 2018 

March 14 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 REVENUE $8.8 MILLION VERSUS I/B/E/S VIEW $7.5 MILLION.QTRLY ‍NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.24 PER BASIC SHARE​.  Full Article

Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS.INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION.INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO'S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY.  Full Article

Inovio Receives Milestone Payment From Medimmune
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2.  Full Article

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article

Inovio pharmaceuticals reports 2017 third quarter financial results
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 third quarter financial results.Q3 loss per share $0.39.Q3 revenue $2.6 million versus $12.5 million.Q3 revenue view $9.4 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Inovio Pharmaceuticals - ‍as of Sept 30, 2017, cash and cash equivalents and short-term investments were $141.9 million versus $104.8 million as of Dec 31, 2016​.  Full Article

Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.  Full Article